Your Health, We Care
Release date: 2025-04-15 14:38:36 Recommended: 33
This article analyzes the clinical application and economic cost of finerenone.
The use of this drug should be strictly in accordance with medical standards.
Individuals with renal impairment and proteinuria have shown potential to slow disease progression in multiple clinical trials. It is indicated for patients with glomerular filtration rate in the range of 25 to 90 mL/min/1.73 m².
People with comorbid type 2 diabetes and cardiovascular risk factors may benefit. The study data showed that the incidence of cardiovascular events was reduced by about 14% after treatment in these patients.
A serum potassium concentration of less than 5.0 mmol/L must be met at the same time, and no strong CYP3A4 inhibitors are used. A history of adrenal insufficiency warrants careful evaluation.
Standardized medication requires comprehensive consideration of many factors.
The starting dose is usually 10 mg daily and can be increased to 20 mg based on serum potassium monitoring. For patients weighing less than 60 kg, it is recommended to maintain a lower dose. The cost of basic medication is in the range of $120-$240 per month.
Electrolyte levels should be measured weekly for the first 4 weeks of treatment and monthly after stabilization. Renal function assessment should be done quarterly, and imaging tests are recommended to be done semi-annually.
The original drug costs about $280 per month, and the generic drug price can be reduced to $180. Some health insurance plans cover 60-80% of the cost, and the out-of-pocket portion costs an average of about $50-80 per month.
Proper use of the drug requires professional medical guidance, and individualized treatment should balance treatment effectiveness with affordability. Regular monitoring and dose optimization are key to maintaining long-term efficacy, and medical decisions need to be based on a complete clinical assessment.
